Zobrazeno 1 - 10
of 19
pro vyhledávání: '"C M, Foris"'
Autor:
C. M. Foris, Shelley R. Rabel, G. Creston Campbell, Gregory A. Nemeth, Susan M. Rowe, Michael B. Maurin, J. Gerry Everlof, Rodney Vickery
Publikováno v:
Journal of Pharmaceutical Sciences. 91:2599-2604
Roxifiban was found to exist in two polymorphic forms. The polymorphs were detected by X-ray powder diffraction and solid-state carbon nuclear magnetic resonance. A slight difference between the two polymorphs was also detected by isothermal microcal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9eced34e748fdc6094b327cf22de55d9
https://doi.org/10.1002/jps.10078
https://doi.org/10.1002/jps.10078
Autor:
T.M. Sielecki, R.D. Vickery, C. M. Foris, R.E. Olson, Z. G. Li, R. L. Harlow, Michael B. Maurin, L. Liang, Junke Liu
Publikováno v:
Journal of Pharmaceutical Sciences. 89:1237-1242
In the course of the development of Lumaxis™ (roxifiban), the physical state of XP280 (the besylate salt of the active metabolites of roxifiban) and SC887 (the mesylate salt of the free base of roxifiban) were characterized. Powder X‐ray diffract
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ace9d527940d7227aa9e4c1ea0cf8136
https://doi.org/10.1002/1520-6017(200010)89:10<1237::aid-jps1>3.0.co
https://doi.org/10.1002/1520-6017(200010)89:10<1237::aid-jps1>3.0.co
Publikováno v:
Pharmaceutical Research. 13:481-484
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c75733228a14e74d5769a4d8de2adb7b
https://doi.org/10.1023/a:1016021432262
https://doi.org/10.1023/a:1016021432262
Publikováno v:
Journal of Crystal Growth. 112:309-315
We report the growth of thin (4–20 μm) epitaxial films of KTiOAs x P 1− x O 4 on KTiOPO 4 substrates. The films were grown at ∼ 850°C by liquid phase epitaxy using the tungstate and the pure arsenate-phosphate self-fluxes. Typical growth rate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::607eb12a2b5c90fb4d6adf1e730efa4b
https://doi.org/10.1016/0022-0248(91)90306-p
https://doi.org/10.1016/0022-0248(91)90306-p
Autor:
R.D. Vickery, H. Li, Michael B. Maurin, P. Ma, B.H. Toby, C. M. Foris, Z. G. Li, R. L. Harlow
Publikováno v:
Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada. 8(2)
Electron diffraction has been recently used in the pharmaceutical industry to study the polymorphism in crystalline drug substances. While conventional X-ray diffraction patterns could not be used to determine the cell parameters of two forms of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87bbae82e75d22992ecc6e03af56e56b
https://pubmed.ncbi.nlm.nih.gov/12533242
https://pubmed.ncbi.nlm.nih.gov/12533242
Publikováno v:
Die Makromolekulare Chemie, Rapid Communications. 13:159-161
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9759b31d3c6414a4b9959f811018fad0
https://doi.org/10.1002/marc.1992.030130304
https://doi.org/10.1002/marc.1992.030130304
Autor:
Z G, Li, L, Liang, R L, Harlow, C M, Foris, R E, Olson, T M, Sielecki, J, Liu, R D, Vickery, M B, Maurin
Publikováno v:
Journal of pharmaceutical sciences. 89(10)
In the course of the development of Lumaxistrade mark (roxifiban), the physical state of XP280 (the besylate salt of the active metabolites of roxifiban) and SC887 (the mesylate salt of the free base of roxifiban) were characterized. Powder X-ray dif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5c05caa80856b59e1c9de6378cf3f8fb
https://pubmed.ncbi.nlm.nih.gov/10980498
https://pubmed.ncbi.nlm.nih.gov/10980498
Autor:
R.D. Vickery, H. Li, B.H. Toby, Z. G. Li, C. M. Foris, P. Ma, R. L. Harlow, Michael B. Maurin
Publikováno v:
Journal of pharmaceutical sciences. 88(3)
Unit cell parameters of two polymorphs of roxifiban have been determined by a combination of transmission electron microscopy (TEM) single-crystal and synchrotron X-ray powder diffraction techniques. While it was difficult to differentiate the two fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ced521fcc5d3425a77f7ac95461d8ae9
https://pubmed.ncbi.nlm.nih.gov/10052986
https://pubmed.ncbi.nlm.nih.gov/10052986
Publikováno v:
Pharmaceutical research. 13(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8f6ddf903f25e1e27a812cfb508a21cc
https://pubmed.ncbi.nlm.nih.gov/8692746
https://pubmed.ncbi.nlm.nih.gov/8692746
Publikováno v:
Microscopy and Microanalysis. 7:630-631
Efavirenz (Sustiva™) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HrV-infected patients and has been in the market since 1998. Efavirenz exists as three different polymorphs (Forms I, II, III) and a nonstochiomet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::55cc9957fa39657cc22dbb5907da59f0
https://doi.org/10.1017/s1431927600029226
https://doi.org/10.1017/s1431927600029226